It is normal for drugs to be transferred out of the medical insurance catalogue, and 352 kinds of drugs have been transferred out

[industry trends of pharmaceutical network] recently, Beijing Municipal Medical Security Bureau announced the notice of Beijing Municipality on the adjustment of the reimbursement scope of basic medical insurance, work injury insurance and maternity insurance drugs Among them, it is clear that since January 1, 2020, 352 kinds of drugs have been transferred out of the Beijing Medical Insurance catalogue due to their low clinical value, large side effects and easy abuse At the same time, 297 drugs will be added, involving the treatment of major diseases such as cancer and rare diseases In fact, Beijing is not an exception In recent years, many provinces have transferred a large number of drugs out of their local health insurance catalog For example, on December 13, Hunan Medical Insurance Bureau and the Department of human resources and Social Security jointly issued a notice that they would digest the supplementary medical insurance drugs of the original province year by year, preferentially remove the first batch of national key monitoring catalog varieties, transfer out the original catalog varieties of the province that have entered the national drug catalog, and then classify them as "drug parts in digestion period" These varieties will be digested year by year within three years according to the national regulations, and clear up the medical insurance scope Wai There are 404 varieties involved, of which 212 are western medicine and 192 are Chinese patent medicine On December 17, Sichuan Medical Insurance Bureau issued a notice that the national drug catalog will be implemented from January 1, 2020, and 275 Western medicines and 71 Chinese patent medicines will be removed from the Sichuan Medical insurance catalog It is clear in the document that if the provincial supplementary catalogue has been included in the national drug catalogue, it shall be implemented in accordance with the national regulations; if it has not been included, it shall be implemented temporarily in accordance with the original regulations and gradually digested within three years; the deleted varieties in the national drug catalogue shall not be implemented In fact, in order to better coordinate drug prices Previously, the state health insurance bureau has explicitly cancelled the local authority to supplement the medical insurance catalog: each region shall not make its own catalog or add drugs in the catalog by flexible methods, nor adjust the limited payment scope of drugs in the catalog The class B drugs added according to the regulations in the original provincial drug catalogue shall be gradually digested within 3 years In the process of digestion, provinces should give priority to adjusting the payment scope of drugs included in the national key monitoring scope Therefore, a large number of drugs have been transferred out of many provinces In fact, the country has set a three-year buffer period, the main purpose is to let those who go out still have the opportunity to come in As long as they meet the standard of drug base catalogue, do well in secondary research and development, evidence-based medicine, etc., they can still enter the medical insurance again The goal of national reform is to let the health insurance fund be used on the cutting edge, not to kill some enterprises In this regard, the industry also said that the non urgent, unimportant, auxiliary clinical efficacy is not clear, and the impact on patients' costs is limited It will be the future policy trend to transfer out the varieties first However, if the supplementary varieties fail to enter the national health insurance catalogue within three years, it will be more dangerous for pharmaceutical enterprises From the current point of view, the medical insurance bureau has lost the super national treatment of the original research drugs through the 4 + 7 volume procurement; on the other hand, it has blocked the way of "saving the country by curve" of some varieties by focusing on the monitoring of the rational drug use catalogue and prohibiting the local supplement of medical insurance varieties In fact, it has been very clear that the attitude towards the future development direction of drugs is to let enterprises make valuable and innovative products; only when enterprises embrace national policies, do consistency evaluation, do consistency evaluation, and do innovation, can they win from the competition.